Related references
Note: Only part of the references are listed.Viral suppression rates in a safety-net HIV clinic in San Francisco destabilized during COVID-19
Matthew A. Spinelli et al.
AIDS (2020)
Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial
Michael Aboud et al.
LANCET INFECTIOUS DISEASES (2019)
Homelessness at diagnosis is associated with death among people with HIV in a population-based study of a US city
Matthew A. Spinelli et al.
AIDS (2019)
Evaluating the Impact of Housing Status on Gonorrhea and Chlamydia Screening in an HIV Primary Care Setting
Angelo Asa Clemenzi-Allen et al.
SEXUALLY TRANSMITTED DISEASES (2019)
Degree of Housing Instability Shows Independent Dose-Response With Virologic Suppression Rates Among People Living With Human Immunodeficiency Virus
Angelo Clemenzi-Allen et al.
OPEN FORUM INFECTIOUS DISEASES (2018)
Reassessing the Global Mortality Burden of the 1918 Influenza Pandemic
Peter Spreeuwenberg et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2018)
HIV Viral Suppression Trends Over Time Among HIV-Infected Patients Receiving Care in the United States, 1997 to 2015 A Cohort Study
Robin M. Nance et al.
ANNALS OF INTERNAL MEDICINE (2018)
Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study
Benoit Trottier et al.
ANTIVIRAL THERAPY (2017)
Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study
Jean-Michel Molina et al.
LANCET HIV (2015)
Factors associated with the accuracy of physicians' predictions of patient adherence
L. Alison Phillips et al.
PATIENT EDUCATION AND COUNSELING (2011)
Long-Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment-Experienced Patients with Drug-Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials
Roy T. Steigbigel et al.
CLINICAL INFECTIOUS DISEASES (2010)
Share Paper
